Estimated read time: 2-3 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[SU] AWD TRI
-- WITH PHOTO -- TO HEALTH, AND NATIONAL EDITORS:
Accelovance Nominated for TWO 2014 Vaccine Industry Excellence (ViE)
ROCKVILLE, Md., March 6, 2014 /PRNewswire-USNewswire/ -- Accelovance,
a therapeutically focused clinical research organization (CRO), has
been named a finalist for two Vaccine Industry Excellence (ViE)
Awards, with nominations for "Best Contract Research Organization" and
"Best Clinical Trial Network and Site."
This is the seventh consecutive year Accelovance has been honored as
an award nominee at the World Vaccine Congress, winning for "Best
Contract Research Organization" in 2009, 2010, and 2011, as well as
receiving a "Highly Recommended" distinction in 2013.
"We're honored to be nominated for these two awards, which highlight
the continued depth and breadth of our leadership and experience
within the conduct of vaccine trials. Our dedication to serving the
needs and advancing the research of Sponsors in this important
therapeutic area continues to be validated by this global Conference
distinction," commented Stephen J. Trevisan, Accelovance President and
Chief Executive Officer.
Accelovance will be evaluated by an international panel for quality of
services, performance, client satisfaction, Sponsor relationships, and
the overall value brought to study Sponsors. Accelovance is well known
within the industry for its experience in managing vaccine trials, for
successful clinical oversight, patient enrollment and retention, and
for providing full service solutions to Sponsors. Award winners will
be announced at the 14th Annual World Vaccine Congress being held in
Washington, D.C.March 24-26, 2014.
Accelovance is an award-winning, niche CRO focused primarily in
vaccines, oncology, and general medicine. Accelovance operates four
core service divisions; a full-service Contract Research Organization,
Site Management Organization, Patient Recruitment, and Call Center
that positively impact the advancement of clinical research. As a
clinical services provider to the pharmaceutical and biotech
industries, Accelovance offers comprehensive services including
management and implementation of Phase I-IV clinical trials, patient
recruitment/retention solutions, and a Clinical Call Center that can
assist in recruitment, retention, and post-marketing surveillance.
Established in 2005 with a corporate mission to improve the quality
and predictability in clinical research, Accelovance is a privately
held company headquartered in Rockville, Maryland. Accelovance has
made significant strides in the industry by combining strong business
and operational perspective with clinical and medical expertise.
Press Contact: Michael Keens, VP Business Development 240.238.4941
firstname.lastname@example.org Twitter: @Accelovance
/Web Site: http://www.accelovance.com
ST: Maryland District of Columbia
SU: AWD TRI
-- DC78163 --
0000 03/06/2014 14:00:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.